Structural biology of the tumor suppressor p53.

The tumor suppressor protein p53 induces or represses the expression of a variety of target genes involved in cell cycle control, senescence, and apoptosis in response to oncogenic or other cellular stress signals. It exerts its function as guardian of the genome through an intricate interplay of independently folded and intrinsically disordered functional domains. In this review, we provide insights into the structural complexity of p53, the molecular mechanisms of its inactivation in cancer, and therapeutic strategies for the pharmacological rescue of p53 function in tumors. p53 emerges as a paradigm for a more general understanding of the structural organization of modular proteins and the effects of disease-causing mutations.

[1]  L Serrano,et al.  The folding of an enzyme. II. Substructure of barnase and the contribution of different interactions to protein stability. , 1992, Journal of molecular biology.

[2]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[3]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[4]  J. Shay,et al.  A temperature‐sensitive mutant of human p53. , 1994, The EMBO journal.

[5]  C. Arrowsmith,et al.  Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.

[6]  A. Levine,et al.  Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[8]  G. Marius Clore,et al.  Refined solution structure of the oligomerization domain of the tumour suppressor p53 , 1995, Nature Structural Biology.

[9]  Y. Sung,et al.  Transactivation Ability of p53 Transcriptional Activation Domain Is Directly Related to the Binding Affinity to TATA-binding Protein (*) , 1995, The Journal of Biological Chemistry.

[10]  A. Gronenborn,et al.  Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  N. Pavletich,et al.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.

[12]  A. Fersht,et al.  Structural and energetic responses to cavity-creating mutations in hydrophobic cores: observation of a buried water molecule and the hydrophilic nature of such hydrophobic cavities. , 1996, Biochemistry.

[13]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[14]  N. Pavletich,et al.  Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.

[15]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Halazonetis,et al.  Structure–based rescue of common tumor–derived p53 mutants , 1996, Nature Medicine.

[17]  H. Sakamoto,et al.  Effect of Phosphorylation on Tetramerization of the Tumor Suppressor Protein p53 , 1997, Journal of protein chemistry.

[18]  Wei Gu,et al.  Synergistic activation of transcription by CBP and p53 , 1997, Nature.

[19]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[20]  A. Fersht,et al.  Thermodynamic stability of wild-type and mutant p53 core domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[22]  E. Stavridi,et al.  Hydrophobic side‐chain size is a determinant of the three‐dimensional structure of the p53 oligomerization domain , 1997, The EMBO journal.

[23]  F. Kashanchi,et al.  Phosphorylation of p53 Serine 15 Increases Interaction with CBP* , 1998, The Journal of Biological Chemistry.

[24]  A. Fersht,et al.  Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Boeke,et al.  Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations , 1998, The EMBO journal.

[26]  A. Fersht,et al.  Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain , 1998, The EMBO journal.

[27]  C. Prives,et al.  Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay , 1998, Oncogene.

[28]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[29]  Xinbin Chen,et al.  Identification of a Novel p53 Functional Domain That Is Necessary for Mediating Apoptosis* , 1998, The Journal of Biological Chemistry.

[30]  M. Grütter,et al.  Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. , 1998, Acta crystallographica. Section D, Biological crystallography.

[31]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[32]  B. Matthews,et al.  The response of T4 lysozyme to large‐to‐small substitutions within the core and its relation to the hydrophobic effect , 1998, Protein science : a publication of the Protein Society.

[33]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[34]  M. Clarke,et al.  A Bipartite Nuclear Localization Signal Is Required for p53 Nuclear Import Regulated by a Carboxyl-terminal Domain* , 1999, The Journal of Biological Chemistry.

[35]  Alan R. Fersht,et al.  Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53 , 1999, Nature Structural Biology.

[36]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[37]  J. Jen,et al.  Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Fersht,et al.  Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  V. Zhurkin,et al.  p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Kyou-Hoon Han,et al.  Local Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53* , 2000, The Journal of Biological Chemistry.

[41]  K. Sakaguchi,et al.  Damage-mediated Phosphorylation of Human p53 Threonine 18 through a Cascade Mediated by a Casein 1-like Kinase , 2000, The Journal of Biological Chemistry.

[42]  A. Fersht,et al.  Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations , 2000, The EMBO journal.

[43]  A. Fersht,et al.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.

[44]  M. Sudol,et al.  The importance of being proline: the interaction of proline‐rich motifs in signaling proteins with their cognate domains , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  R. Goodman,et al.  CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.

[46]  R. Copeland,et al.  Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. , 2000, Archives of biochemistry and biophysics.

[47]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[48]  David J. Weber,et al.  Structure of the negative regulatory domain of p53 bound to S100B(ββ) , 2000, Nature Structural Biology.

[49]  R. Huber,et al.  High Thermostability and Lack of Cooperative DNA Binding Distinguish the p63 Core Domain from the Homologous Tumor Suppressor p53* , 2001, The Journal of Biological Chemistry.

[50]  P. Chène,et al.  The role of tetramerization in p53 function , 2001, Oncogene.

[51]  A. Fersht,et al.  Rescuing the function of mutant p53 , 2001, Nature Reviews Cancer.

[52]  J. Espinosa,et al.  Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. , 2001, Molecular cell.

[53]  T. Hupp,et al.  Inhibition of p53‐dependent transcription by BOX‐I phospho‐peptide mimetics that bind to p300 , 2001, EMBO reports.

[54]  C. Klein,et al.  NMR Spectroscopy Reveals the Solution Dimerization Interface of p53 Core Domains Bound to Their Consensus DNA* , 2001, The Journal of Biological Chemistry.

[55]  Y. Xiong,et al.  A p53 Amino-Terminal Nuclear Export Signal Inhibited by DNA Damage-Induced Phosphorylation , 2001, Science.

[56]  S. Berger,et al.  Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. , 2001, Molecular cell.

[57]  T. Davison,et al.  Structure and functionality of a designed p53 dimer. , 2001, Journal of molecular biology.

[58]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[59]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.

[60]  Galina Selivanova,et al.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.

[61]  A. Fersht,et al.  Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. , 2002, Journal of molecular biology.

[62]  A. Fersht,et al.  A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Patrick W. Lee,et al.  Biogenesis of p53 Involves Cotranslational Dimerization of Monomers and Posttranslational Dimerization of Dimers , 2002, The Journal of Biological Chemistry.

[64]  Johannes Buchner,et al.  p53 contains large unstructured regions in its native state. , 2002, Journal of molecular biology.

[65]  L. Serpell,et al.  Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor , 2002, The EMBO journal.

[66]  Ivo Tews,et al.  Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. , 2002, Biochemistry.

[67]  D. Livingston,et al.  Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. , 2002, Genes & development.

[68]  A. Fersht,et al.  Kinetic Instability of p53 Core Domain Mutants , 2003, Journal of Biological Chemistry.

[69]  A. Inga,et al.  Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Johannes Buchner,et al.  The N-terminal domain of p53 is natively unfolded. , 2003, Journal of molecular biology.

[71]  Stewart N Loh,et al.  Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. , 2003, Biochemistry.

[72]  J. Gariépy,et al.  A Stable Human p53 Heterotetramer Based on Constructive Charge Interactions within the Tetramerization Domain* , 2003, The Journal of Biological Chemistry.

[73]  A. Fersht,et al.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[74]  K. Wiman,et al.  Small molecules that reactivate mutant p53. , 2003, European journal of cancer.

[75]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  P. Jeffrey,et al.  Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1. , 2004, Structure.

[77]  Ting Wang,et al.  A global suppressor motif for p53 cancer mutants. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[78]  A. Fersht,et al.  Cooperative binding of tetrameric p53 to DNA. , 2004, Journal of molecular biology.

[79]  Paul W Brandt-Rauf,et al.  NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. , 2004, Biochemistry.

[80]  J. Milner,et al.  Remodelling chromatin on a global scale: a novel protective function of p53. , 2004, Carcinogenesis.

[81]  Roberto Sanchez,et al.  Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. , 2004, Molecular cell.

[82]  A. Fersht,et al.  Regulation of DNA binding of p53 by its C-terminal domain. , 2004, Journal of molecular biology.

[83]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[84]  C. Prives,et al.  p53 linear diffusion along DNA requires its C terminus. , 2004, Molecular cell.

[85]  W. Deppert,et al.  Transcriptional activities of mutant p53: When mutations are more than a loss , 2004, Journal of cellular biochemistry.

[86]  R. Poon,et al.  How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer? , 2004, Molecular and Cellular Biology.

[87]  A. Barberis,et al.  CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity , 2004, Journal of Negative Results in Biomedicine.

[88]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[89]  S. Kato,et al.  Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* , 2004, Journal of Biological Chemistry.

[90]  A. Fersht,et al.  Crystal Structure of a Superstable Mutant of Human p53 Core Domain , 2004, Journal of Biological Chemistry.

[91]  W. Gu,et al.  Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[92]  J. Butler,et al.  Kinetic partitioning during folding of the p53 DNA binding domain. , 2005, Journal of molecular biology.

[93]  A. Fersht,et al.  Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations* , 2005, Journal of Biological Chemistry.

[94]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[95]  Jiandong Chen,et al.  p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53 , 2005, Molecular Cancer Therapeutics.

[96]  W. Gu,et al.  Functional Analysis of the Roles of Posttranslational Modifications at the p53 C Terminus in Regulating p53 Stability and Activity , 2005, Molecular and Cellular Biology.

[97]  G. Wahl,et al.  The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[98]  A. Fersht,et al.  Modulation of binding of DNA to the C-terminal domain of p53 by acetylation. , 2005, Structure.

[99]  A. Fersht,et al.  Comparative binding of p53 to its promoter and DNA recognition elements. , 2005, Journal of molecular biology.

[100]  C. Arrowsmith,et al.  Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[101]  T. Kuwana,et al.  PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53 , 2005, Science.

[102]  Jean-Christophe Marine,et al.  Mdmx as an essential regulator of p53 activity. , 2005, Biochemical and biophysical research communications.

[103]  G. Li,et al.  Mutant p53 melanoma cell lines respond differently to CP‐31398‐induced apoptosis , 2005, The British journal of dermatology.

[104]  Marc S. Cortese,et al.  Flexible nets , 2005, The FEBS journal.

[105]  Antonina Andreeva,et al.  Core domain interactions in full-length p53 in solution , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[106]  L. Nilsson,et al.  Effect of Zn2+ on DNA recognition and stability of the p53 DNA-binding domain. , 2006, Biochemistry.

[107]  A. Fersht,et al.  Structural basis for understanding oncogenic p53 mutations and designing rescue drugs , 2006, Proceedings of the National Academy of Sciences.

[108]  Ronen Marmorstein,et al.  Structure of the p53 Core Domain Dimer Bound to DNA*♦ , 2006, Journal of Biological Chemistry.

[109]  A. Joachimiak,et al.  Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. , 2006, Genes & development.

[110]  J. Freudenheim,et al.  p53 Mutation Analysis in Breast Tumors by a DNA Microarray Method , 2006, Cancer Epidemiology Biomarkers & Prevention.

[111]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[112]  Alan R. Fersht,et al.  Solution structure of p53 core domain: Structural basis for its instability , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[113]  C. Prives,et al.  Mutational Analysis of the p53 Core Domain L1 Loop* , 2006, Journal of Biological Chemistry.

[114]  G. Sal,et al.  Some p53-binding proteins that can function as arbiters of life and death , 2006, Cell Death and Differentiation.

[115]  G. Wahl,et al.  Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 , 2006, Cell Death and Differentiation.

[116]  Christopher J. Oldfield,et al.  Intrinsic disorder in transcription factors. , 2006, Biochemistry.

[117]  Xin Lu,et al.  ASPP [corrected] and cancer. , 2006, Nature reviews. Cancer.

[118]  J. Roth.  Adenovirus p53 gene therapy , 2006, Expert opinion on biological therapy.

[119]  K. Wiman,et al.  Strategies for therapeutic targeting of the p53 pathway in cancer , 2006, Cell Death and Differentiation.

[120]  Marc S. Cortese,et al.  Analysis of molecular recognition features (MoRFs). , 2006, Journal of molecular biology.

[121]  Ronen Marmorstein,et al.  Acetylation of the p53 DNA-binding domain regulates apoptosis induction. , 2006, Molecular cell.

[122]  M. Kitayner,et al.  Structural basis of DNA recognition by p53 tetramers. , 2006, Molecular cell.

[123]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[124]  N. Gueven,et al.  The complexity of p53 stabilization and activation , 2006, Cell Death and Differentiation.

[125]  Yi Tang,et al.  Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. , 2006, Molecular cell.

[126]  Henning Tidow,et al.  Effects of Oncogenic Mutations and DNA Response Elements on the Binding of p53 to p53-binding Protein 2 (53BP2)* , 2006, Journal of Biological Chemistry.

[127]  Yigong Shi,et al.  Structural Basis of Competitive Recognition of p53 and MDM2 by HAUSP/USP7: Implications for the Regulation of the p53–MDM2 Pathway , 2006, PLoS biology.

[128]  A. Levine,et al.  The P53 pathway: what questions remain to be explored? , 2006, Cell Death and Differentiation.

[129]  Alberto Inga,et al.  The Biological Impact of the Human Master Regulator p53 Can Be Altered by Mutations That Change the Spectrum and Expression of Its Target Genes , 2006, Molecular and Cellular Biology.

[130]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[131]  Z. Weng,et al.  A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome , 2006, Cell.

[132]  R. Milo,et al.  Oscillations and variability in the p53 system , 2006, Molecular systems biology.

[133]  Sebastian Mayer,et al.  Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains* , 2006, Journal of Biological Chemistry.

[134]  Shili Duan,et al.  Molecular recognition of p53 and MDM2 by USP7/HAUSP , 2006, Nature Structural &Molecular Biology.

[135]  Wei Gu,et al.  p53 ubiquitination: Mdm2 and beyond. , 2006, Molecular cell.

[136]  Ronen Marmorstein,et al.  High-resolution structure of the p53 core domain: implications for binding small-molecule stabilizing compounds. , 2006, Acta crystallographica. Section D, Biological crystallography.

[137]  Toshiaki Hara,et al.  Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. , 2006, Molecular cell.

[138]  Horst Kessler,et al.  WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization* , 2006, Journal of Biological Chemistry.

[139]  G. Wahl,et al.  Mouse Mutants Reveal that Putative Protein Interaction Sites in the p53 Proline-Rich Domain Are Dispensable for Tumor Suppression , 2006, Molecular and Cellular Biology.

[140]  E. Orlova,et al.  The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity , 2006, The EMBO journal.

[141]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[142]  Sebastian Mayer,et al.  Correlation of levels of folded recombinant p53 in escherichia coli with thermodynamic stability in vitro. , 2007, Journal of molecular biology.

[143]  M. Olivier,et al.  The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. , 2007, Cancer letters.

[144]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[145]  Ruth Nussinov,et al.  Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets , 2007, Nucleic acids research.

[146]  David R Bickers,et al.  CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. , 2007, The Journal of clinical investigation.

[147]  L. R. Dearth,et al.  Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. , 2007, Carcinogenesis.

[148]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[149]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[150]  A. Fersht,et al.  Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53 , 2007, Proceedings of the National Academy of Sciences.

[151]  L. Vassilev,et al.  Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53 , 2007, Molecular Cancer Therapeutics.

[152]  A. Fersht,et al.  Quaternary structures of tumor suppressor p53 and a specific p53–DNA complex , 2007, Proceedings of the National Academy of Sciences.

[153]  Ying Wang,et al.  Structure of the human p53 core domain in the absence of DNA. , 2007, Acta crystallographica. Section D, Biological crystallography.

[154]  V. Rotter,et al.  Transcription regulation by mutant p53 , 2007, Oncogene.

[155]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[156]  Shunsuke Kato,et al.  The screening of the second‐site suppressor mutations of the common p53 mutants , 2007, International journal of cancer.

[157]  A Keith Dunker,et al.  Characterization of molecular recognition features, MoRFs, and their binding partners. , 2007, Journal of proteome research.

[158]  V. Dötsch,et al.  Structural evolution of C‐terminal domains in the p53 family , 2007, The EMBO journal.

[159]  A. Fersht,et al.  Structure–function–rescue: the diverse nature of common p53 cancer mutants , 2007, Oncogene.

[160]  A. Fersht,et al.  Comparative Biophysical Characterization of p53 with the Pro-apoptotic BAK and the Anti-apoptotic BCL-xL* , 2007, Journal of Biological Chemistry.